Trials / Completed
CompletedNCT00863161
Renal Impairment Study
A Phase I, Open Label, Non-randomized, Parallel Group, Pharmacokinetic Study in Subjects With Normal Renal Function, Moderate or Severe Renal Impairment Receiving a Single Dose of Oral 130 mg AZD3355
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to see how quickly AZD3355 is taken up in to the blood and leaves the blood in people with normal kidney function or with different degrees of reduced kidney function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD3355 | capsule, oral, single dose |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2009-03-17
- Last updated
- 2011-01-24
Locations
3 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00863161. Inclusion in this directory is not an endorsement.